Featured in NEJM Journal Watch: Breaking News from ACC 2014 — Physician’s First Watch
Featured in NEJM Journal Watch: Breaking News from ACC 2014
By the NEJM Journal Watch Editors
NEJM Journal Watch is covering the latest trials from the American College of Cardiology conference in Washington, D.C. Here are this weekend's highlights:
SYMPLICITY HTN-3: Catheter-based renal denervation did not lower blood pressure significantly in a sham-controlled trial.
U.S. CoreValve High-Risk Study: A new self-expanding bioprosthesis for transcatheter aortic-valve replacement beats surgery in patients with severe aortic stenosis.
CHOICE: Procedural outcomes at 30 days after transcatheter aortic valve replacement favored a balloon-expandable device (Sapien) over a self-expandable one (CoreValve), but longer and larger trials are needed to assess clinical outcomes.
MADIT-CRT: In an extended follow-up of patients with mild heart failure, cardiac resynchronization therapy reduced mortality in patients with left bundle-branch block, but not in those without it.
STABILITY: In this prospective randomized trial among patients with stable CHD, lipoprotein-associated phospholipase A2 inhibition did not improve the primary clinical outcomes.